- Country: Belgium
- Summary: Ex Post Evaluation: Eu Competition Enforcement and Acquisitions of Innovative Competitors in the Pharma Sector Leading to the Discontinuation of Overlapping Drug Research and Development Projects
- BET Ref No: 55974427
- Deadline: 18 Oct 2021
- Financier: European Commission
- Purchaser Ownership: Government
- Tender Value: EUR 500000.00
- Notice Type: Tender
- Document Ref. No.: 398626-2021
- Purchaser's Detail:Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
- Description:
- Document Type : Contract notice
Title : Ex Post Evaluation: EU Competition Enforcement and Acquisitions of Innovative Competitors in the Pharma Sector Leading to the Discontinuation of Overlapping Drug Research and Development Projects
Reference Number : COMP/2021/OP/0002
Contract Type : Services
Estimated Value : 500000.00 - EUR
Description : Empirical research by Cunningham et al. (2021) suggests that in the pharmaceutical industry a considerable number of acquisitions might have as their object or effect the discontinuation of overlapping drug R&D projects to the detriment of innovation competition and ultimately consumers. Such acquisitions are commonly referred to as ‘killer acquisitions-. The study aims to determine what are the typical features of such killer acquisitions and obtain evidence on the prevalence of such acquisitions, as this would allow the Commission to determine which transactions in the pharmaceutical industry deserve closer scrutiny. A second objective of the study is to conduct ex post evaluations of selected past merger decisions. These case studies aim to assess whether in the concentrations notified to and examined by the Commission under the EU Merger Regulation, the Commission correctly anticipated the risks of possible discontinuations of competing lines of drug R&D projects.
79311410 - Economic impact assessment
79310000 - Market research services
79419000 - Evaluation consultancy services
33600000 - Ph... - Documents:
If you are registered member, kindly login to view full details of this tender notice:
CLICK HERE TO LOGINEx Post Evaluation: Eu Competition Enforcement and Acquisitions of Innovative Competitors in the Pharma Sector Leading to the Discontinuation of Overlapping Drug Research and Development Projects - Belgium Tender
The EUROPEAN COMMISSION, DIRECTORATE-GENERAL FOR COMPETITION (COMP), a Government sector organization in Belgium, has announced a new tender for Ex Post Evaluation: Eu Competition Enforcement and Acquisitions of Innovative Competitors in the Pharma Sector Leading to the Discontinuation of Overlapping Drug Research and Development Projects. This tender is published on BelgiumTenders under BET Ref No: 55974427 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2021-10-18.
The estimated tender value is EUR 500000.00, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.
